Open Accessibility Menu

Coronavirus (COVID-19) Update - We are open with your safety in mind.

Click here to learn more.

  • Certified ALS Center Program
    Certified ALS Center Program
  • Level 4 Epilepsy Center - national association of epilepsy centers
    National Association of Epilepsy Centers
  • Comprehensive Stroke Center
  • AANEM EDX Lab Accreditation - exemplary status
    AANEM EDX Lab Accreditation

Mission Statement

High Quality Headache Care IN Washington DC

The GW Medical Faculty Associates Headache Center was established in July 2015 to fulfill two primary objectives:

  • To provide citizens of the region with expert consultative care in the area of headache medicine
  • To raise the existing standard of care for headache through research.

Approach to Headache Management

In treating patients with headaches and migraine headaches, the GW Headache Center is dedicated to the proposition that patients who take an active role in managing their headache disorder will experience a more favorable clinical outcome than patients who abdicate responsibility for management to the health care provider (HCP). Thus the Center places a strong emphasis on patient education, and from the initial visit onward patients are provided with a variety of educational aids to assist them in understanding the origin of their headaches and how their headache burden may be most effectively reduced. While the Center’s provider is always available to serve as “navigator” and, specifically, to explain the various management options available. Treatment itself is a “two-way street”: a therapeutic alliance in which the patient is an active participant.

New Patients

Patients who come to the Center’s clinics receive a thorough evaluation by neurology providers who have been trained specifically in the field of headache medicine, and each patient is provided with a specific diagnosis and a management plan that is tailored to his/her particular needs.

Established Patients

Patients who have been evaluated at the Center and are having difficulties despite following the management plan designed for them are advised to contact the Center to request assistance. If the patient’s problem cannot be managed by email or phone, he/she will be scheduled for prompt clinic follow-up and a face-to-face evaluation.

Providers Referring to the Center

  • Physicians and other HCPs who refer a patient to the Headache Center’s clinics for evaluation will receive an electronic communication from the Center provider who personally evaluated the patient, and that communication will contain both the provider’s clinical impression and a detailed management plan.
  • Patients referred to the Center’s clinics can be managed in one of two ways: (1) a one-time consultation, wherein a detailed management plan is outlined for the referring HCP, or (2) total comprehensive and continued care for the patient’s headache disorder is assumed by the Center.
  • Referring providers should specify which option they prefer.
  • Patients referred to the Center’s clinics who are eligible for participation in an ongoing clinical research trial and choose to participate will be followed closely by the Center’s providers and research staff for the duration of the study and seen regularly at the GW Headache Research Center, in the Center’s clinics or both. Such follow-up will be conducted in parallel with any care provided by the referring HCP, and that provider will receive regular updates as to the patient’s clinical status while enrolled in the research study.
  • If a patient who was referred to the Center does poorly from the headache standpoint despite implementation of the recommended management plan, the patient’s primary care provider (or the provider who initially referred the patient) is encouraged to refer the patient back to the Center for repeat evaluation.

Co-Directors, The GW Medical Faculty Associates Headache Center:

Amanda Tinsley, M.D.

John F. Rothrock, M.D.

To print this mission statement document, click here.

Conveniently Located

Clinical Trials

  • INSYTE: Management of Parkinson’s Disease Psychosis in Actual Practice (The INSYTE Study)
    The INSYTE Study will examine the current disease progression of Parkinson’s disease Psychosis (PDP), the clinical, economic, and humanistic impact of anti-psychotic therapy in the management of the condition in real-world settings, and the burden of the condition on patients and their caregivers.
    This study will evaluate whether prolonged oral levosimendan can preserve respiratory function more effectively than placebo, resulting in better patient functionality as measured by the ALSFRS-R scale.
  • PENNANT: A Multicenter, Double Blind, Placebo Controlled Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in the Treatment of Subjects With Amyotrophic Lateral Sclerosis
    The purpose of the PENNANT study is to evaluate the safety, tolerability, and effectiveness of the study drug (H.P. Acthar Gel®) in slowing the loss of motor skills or brain function in patients with ALS and to assess whether the study drug can increase an ALS patient’s life expectancy. Eligible participants will either receive the study drug or a placebo (inactive drug).
  • Protocol H8H-MC-LAIJ, Randomized Controlled Trial of Lasmiditan Over Four Migraine Attacks
    The objective of this Phase 3 study is to evaluate the efficacy of lasmiditan 200 mg and 100 mg on migraine headache pain freedom compared to placebo.
    The primary objectives of this study are to characterize the dose-response relationship with respect to efficacy of PSL administered concomitantly with up to 3 anti-epileptic drugs (AEDs) for treatment of observable focal-onset seizures in subjects with drug-resistant epilepsy and to evaluate the efficacy of the 4 selected dose regimens of PSL compared with placebo. The secondary objective is to assess the safety and tolerability of all doses of PSL in relation to placebo.
  • A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Exploring the Efficacy, Safety, and Tolerability of Natalizumab (BG00002) as Adjunctive Therapy in Adult Subjects With Drug-Resistant Focal Epilepsy
    The primary efficacy objective of the study is to determine if adjunctive therapy of natalizumab 300 mg intravenous (IV) infusion every 4 weeks reduces the frequency of seizures in adult subjects with drug-resistant focal epilepsy.
  • Low frequency electrical stimulation of the fornix in Intractable Mesial Temporal Lobe Epilepsy (MTLE)
    To develop a protocol to evaluate the safety and tolerability of low frequency stimulation of the fornix in patients with MTLE.